Related references
Note: Only part of the references are listed.Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune-checkpoint inhibitors and survival in non-small-cell lung cancer
Diego de Miguel-Perez et al.
CANCER (2023)
Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer
Diego de Miguel-Perez et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)
Tumor activated platelets induce vascular mimicry in mesenchymal stem cells and aid metastasis
Avishek Bhuniya et al.
CYTOKINE (2022)
Platelet detection as a new liquid biopsy tool for human cancers
Maoshan Chen et al.
FRONTIERS IN ONCOLOGY (2022)
Dissecting the effects of preconditioning with inflammatory cytokines and hypoxia on the angiogenic potential of mesenchymal stromal cell (MSC)-derived soluble proteins and extracellular vesicles (EVs)
Cansu Gorgun et al.
BIOMATERIALS (2021)
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC
Roy S. Herbst et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer
Clemens Hinterleitner et al.
NATURE COMMUNICATIONS (2021)
Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment
So Yeon Oh et al.
SCIENTIFIC REPORTS (2021)
Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies
Ryotaro Ohkuma et al.
BIOMEDICINES (2021)
Soluble B7-H3 in Ovarian Cancer and Its Predictive Value
O. Kovaleva et al.
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE (2021)
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab
Angela Alama et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
Carlo Genova et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Platelets and Platelet-Derived Extracellular Vesicles in Liver Physiology and Disease
Alexandre Balaphas et al.
HEPATOLOGY COMMUNICATIONS (2019)
Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer
Yusuke Okuma et al.
CLINICAL LUNG CANCER (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Flavia Castro et al.
FRONTIERS IN IMMUNOLOGY (2018)
Clinical significance of serum soluble B7-H3 in patients with osteosarcoma
Ling Wang et al.
CANCER CELL INTERNATIONAL (2018)
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Gang Chen et al.
NATURE (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Serum soluble B7-H4 is a prognostic marker for patients with non-metastatic clear cell renal cell carcinoma
Takeshi Azuma et al.
PLOS ONE (2018)
PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer
Kousaku Mimura et al.
CANCER SCIENCE (2018)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer
Yusuke Okuma et al.
LUNG CANCER (2017)
New B7 Family Checkpoints in Human Cancers
Ling Ni et al.
MOLECULAR CANCER THERAPEUTICS (2017)
B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes
Mehmet Altan et al.
CLINICAL CANCER RESEARCH (2017)
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Joseph L. Benci et al.
CELL (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
K. Abiko et al.
BRITISH JOURNAL OF CANCER (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
B7-H4 as a potential target for immunotherapy for gynecologic cancers: A closer look
Jenessa B. Smith et al.
GYNECOLOGIC ONCOLOGY (2014)
B7-H3-mediated tumor immunology: Friend or foe?
Ling Wang et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Stage-specific embryonic antigen-4 is expressed in basaloid lung cancer and associated with poor prognosis
Sandra Gottschling et al.
EUROPEAN RESPIRATORY JOURNAL (2013)
The Two Faces of Interferon-γ in Cancer
M. Raza Zaidi et al.
CLINICAL CANCER RESEARCH (2011)
Possible involvement of soluble B7-H4 in T cell-mediated inflammatory immune responses
Yosuke Kamimura et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Potential Role of Decoy B7-H4 in the Pathogenesis of Rheumatoid Arthritis: A Mouse Model Informed by Clinical Data
Takeshi Azuma et al.
PLOS MEDICINE (2009)
Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56BrightCD16- cells and display an impaired capability to kill tumor cells
Paolo Carrega et al.
CANCER (2008)
Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum
Guangbo Zhang et al.
IMMUNOLOGY (2008)
The new B7s: Playing a pivotal role in tumor immunity
Dallas B. Flies et al.
JOURNAL OF IMMUNOTHERAPY (2007)
Estimating the relative risk in cohort studies and clinical trials of common outcomes
LA McNutt et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2003)
Regulation of surface and intracellular expression of CTLA-4 on human peripheral T cells
XB Wang et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2001)
B7-H3:: A costimulatory molecule for T cell activation and IFN-γ production
AI Chapoval et al.
NATURE IMMUNOLOGY (2001)